NYSE:MRKPharmaceuticals
Merck’s Oncology Deals And Genomics Push Might Change The Case For Investing In Merck (MRK)
In recent days, Illumina announced the launch of its Billion Cell Atlas, a large-scale CRISPR-based single-cell dataset built with founding participants including Merck, AstraZeneca and Eli Lilly, while reports also surfaced that Merck is in early-stage talks to acquire cancer drug developer Revolution Medicines in a potential US$28.00 billion to US$32.00 billion transaction. Merck also began a Phase 3 trial of its KRAS G12C inhibitor calderasib combined with subcutaneous KEYTRUDA QLEX in...